Wedbush Reduces Earnings Estimates for Apogee Therapeutics

Key Points

• Wedbush has revised its earnings estimates for Apogee Therapeutics, projecting a loss of ($1.21) per share for Q3 2025, which is a decline from its previous estimate of ($0.96).
• The company reported a loss of ($1.13) per share in its most recent quarterly earnings, falling short of the consensus estimate of ($1.03) by ($0.10).
• Despite the earnings cut, Wedbush maintains an "Outperform" rating with a price target of $90.00 for Apogee Therapeutics, which has a consensus buy rating among analysts.

Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) - Research analysts at Wedbush dropped their Q3 2025 earnings per share estimates for shares of Apogee Therapeutics in a research note issued on Monday, August 11th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.21) per share for the quarter, down from their previous estimate of ($0.96). Wedbush has a "Outperform" rating and a $90.00 price target on the stock. The consensus estimate for Apogee Therapeutics' current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics' Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.53) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($4.75) EPS, FY2028 earnings at ($6.13) EPS and FY2029 earnings at ($5.99) EPS.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.10).

APGE has been the topic of several other reports. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, July 7th. BTIG Research boosted their price target on Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $116.00 target price on shares of Apogee Therapeutics in a research report on Wednesday, July 2nd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $99.00.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $37.37 on Thursday. The stock's 50 day moving average price is $40.15 and its 200 day moving average price is $37.96. The firm has a market capitalization of $1.72 billion, a PE ratio of -9.05 and a beta of 1.43. Apogee Therapeutics has a one year low of $26.20 and a one year high of $63.50.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. bought a new stake in shares of Apogee Therapeutics in the 4th quarter valued at approximately $259,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Apogee Therapeutics by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company's stock valued at $1,078,000 after acquiring an additional 931 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Apogee Therapeutics by 3.2% in the 1st quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock valued at $2,032,000 after acquiring an additional 1,665 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Apogee Therapeutics in the 4th quarter valued at approximately $219,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Apogee Therapeutics by 93.3% in the 1st quarter. Bank of New York Mellon Corp now owns 214,231 shares of the company's stock valued at $8,004,000 after acquiring an additional 103,404 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors.

Insider Activity

In other Apogee Therapeutics news, insider Carl Dambkowski sold 10,090 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total value of $454,958.10. Following the transaction, the insider directly owned 238,998 shares of the company's stock, valued at $10,776,419.82. This represents a 4.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 15,540 shares of company stock valued at $658,625. Corporate insiders own 42.77% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.